Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-04

Reporting Person: Quinn William P. (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12698	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.80	2030-07-28	Common Stock (152301)		Direct
Stock Option (Right to Buy)	$4.34	2030-09-02	Common Stock (35714)		Direct
Stock Option (Right to Buy)	$4.34	2030-09-02	Common Stock (42857)		Direct

Footnotes

F1: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: (a) 28,551 of the shares on the one (1) year anniversary of May 4, 2020 (the "Vesting Commencement Date"); and (b) thereafter, an additional 1/36th of the remaining shares will vest upon the Reporting Person completing each month of continuous service following the first one (1) year anniversary of the Vesting Commencement Date.

F2: This shares subject to this option vests over a four-year period with 6,696 shares vesting on June 3, 2021 and the remainder vesting monthly over 39 months from June 3, 2021, subject to the Reporting Person continuing to be a service provider to the Issuer through each such date.

F3: This shares subject to this option vests over a four-year period with 3,751 shares vesting on May 15, 2021 and the remainder vesting monthly over 44 months from May 15, 2021, subject to the Reporting Person continuing to be a service provider to the Issuer through each such date.